Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 400, Issue 1-2, Pages 153-157Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2010.08.032
Keywords
Glycyrrhetinic acid; Chitosan; Poly(ethylene glycol); Liver targeting
Categories
Funding
- National Natural Science Foundation of China [50873048, 51073080]
Ask authors/readers for more resources
Two kinds of glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles (CTS/PEG-GA NPs) were prepared by an ionic gelation process in which the liver targeting ligand glycyrrhetinic acid (GA) was introduced into the nanoparticles at the C-30-carboxyl group (CTS/PEG-GA(c) NPs) or the C-3-hydroxyl group (CTS/PEG-GA(h) NPs). Their characteristics, especially their ability to target the liver, were compared. The results showed that both the CTS/PEG-GA(c) NPs and the CTS/PEG-GA(h) NPs are remarkably targeted to the liver. The accumulation in the liver is 51.3% and 56.5% of the injected dose for the CTS/PEG-GA(c)(4.60%) NPs (the subscript number denotes the GA content as weight percent in nanopartides) and the CTS/PEG-GA(h)(4.57%) NPs at 3 h after injection, respectively. This is nearly 2.6-2.8 times higher than that obtained with the CTS/PEG NPs. According to our results, there is no significant difference between the CTS/PEG-GA(c)NPs and the CTS/PEG-GA(h) NPs in their ability to target the liver, when they were formed under identical conditions. This indicated that the C-3-hydroxyl group in GA has little influence on the targeting ability. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available